190 related articles for article (PubMed ID: 16036566)
1. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
3. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.
Spencer DM; Bilardi RA; Koch TH; Post GC; Nafie JW; Kimura K; Cutts SM; Phillips DR
Mutat Res; 2008 Feb; 638(1-2):110-21. PubMed ID: 17961607
[TBL] [Abstract][Full Text] [Related]
4. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
5. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
[TBL] [Abstract][Full Text] [Related]
6. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for the formation of anthracycline-DNA adducts.
Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR
Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313
[TBL] [Abstract][Full Text] [Related]
8. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
[TBL] [Abstract][Full Text] [Related]
9. Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron.
Taatjes DJ; Gaudiano G; Koch TH
Chem Res Toxicol; 1997 Sep; 10(9):953-61. PubMed ID: 9305576
[TBL] [Abstract][Full Text] [Related]
10. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
[TBL] [Abstract][Full Text] [Related]
11. Barminomycin, a model for the development of new anthracyclines.
Kimura K; Spencer DM; Bilardi R; Swift LP; Box AJ; Brownlee RT; Cutts SM; Phillips DR
Anticancer Agents Med Chem; 2010 Jan; 10(1):70-7. PubMed ID: 19807684
[TBL] [Abstract][Full Text] [Related]
12. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.
Evison BJ; Chiu F; Pezzoni G; Phillips DR; Cutts SM
Mol Pharmacol; 2008 Jul; 74(1):184-94. PubMed ID: 18413664
[TBL] [Abstract][Full Text] [Related]
13. Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA.
Szulawska A; Gniazdowski M; Czyz M
Biochem Pharmacol; 2005 Jan; 69(1):7-18. PubMed ID: 15588709
[TBL] [Abstract][Full Text] [Related]
14. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
[TBL] [Abstract][Full Text] [Related]
15. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
16. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR
Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280
[TBL] [Abstract][Full Text] [Related]
17. Detection of adriamycin-DNA adducts by accelerator mass spectrometry.
Coldwell K; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Methods Mol Biol; 2010; 613():103-18. PubMed ID: 19997880
[TBL] [Abstract][Full Text] [Related]
18. Sequence specificity of adriamycin-DNA adducts in human tumor cells.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Mol Cancer Ther; 2003 Jul; 2(7):661-70. PubMed ID: 12883039
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
[TBL] [Abstract][Full Text] [Related]
20. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.
Evison BJ; Mansour OC; Menta E; Phillips DR; Cutts SM
Nucleic Acids Res; 2007; 35(11):3581-9. PubMed ID: 17483512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
